Neurocrine falls 29% on Phase IIb tardive dyskinesia miss
This article was originally published in Scrip
Executive Summary
Neurocrine Biosciences fell 29% in after-hours trading on 9 September after the company said its 50mg dose of NBI-98854 for the treatment of tardive dyskinesia missed the six-week primary endpoint in a Phase IIb clinical trial, but a 100mg dose provided statistically significant improvements without worsening patients' schizophrenia after just two weeks of therapy.